Regeneron Pharmaceuticals, Inc.
NASDAQ:REGNBiotechnology
-$5.45 today
- Market cap
- $97.80B
- Beta
- 0.24
- P/E (TTM)
- 14.2
- EPS (TTM)
- $42.53
- Dividend yield
- 0.60%
Volume 0.70M
Average 0.91M
REGN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Regeneron Pharmaceuticals, Inc.NASDAQ: REGN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $1.66B rose 0.3% year over year, behind the +6.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 71.9% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- EBITDA amounted to 40.6% of revenue in FY2025, up 3.1 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 19 analysts of $8.93B (+53.5%) for the fiscal year ending Dec 2026, a step up from the +9.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.66B+71.9% QoQ
- Last fiscal yearDec 2025
- $5.82B+9.4% YoY
- LTMJun 2026
- $5.75B+6.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.3% | +8.1% | +7.8 pp |
| 1 year | +9.4% | +53.5% | +44.1 pp |
| 3-year CAGR | +3.4% | +20.5% | +17.0 pp |
| 5-year CAGR | +16.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 5.82B USD
- Year-over-year change
- +9.4%
- 4-year CAGR
- -11.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.82B | +9.4% |
| FY2024 | 2024-12-31 | 5.32B | +13.3% |
| FY2023 | 2023-12-31 | 4.69B | -10.8% |
| FY2022 | 2022-12-31 | 5.26B | -45.6% |
| FY2021 | 2021-12-31 | 9.67B | — |
EBITDA vs competitors
How REGN compares with its peers on the latest reported figures
- REGN's LTM Jun 2026 EBITDA of $5.75B is the 4th highest of the 9 companies compared; the peer median is $1.64B.
- Its year-over-year change of +6.1% is the 3rd highest of 8, against a peer median of -42.2%.
- EBITDA amounts to 37.0% of revenue for REGN, versus a peer median of 37.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.26B | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | $5.75B | +6.1% | +3.4% | 37.0% | |
| LTM Jun 2026 | $1.96B | -42.2% | -5.9% | 19.7% | |
| LTM Jun 2026 | $1.33B | -87.8% | +15.3% | 4.4% | |
| LTM Jun 2026 | $1.22B | — | -43.3% | 29.5% | |
| LTM Mar 2026 | -$260.06M | -79.4% | — | 3415.1% | |
| LTM Mar 2026 | -$274.24M | -55.5% | — | 527.0% | |
| Peer median (excluding REGN) | $1.64B | -42.2% | +13.4% | 37.2% | |
Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.07B | 12.17B | 13.12B | 14.2B | 14.34B |
| Cost of Revenue | 2.72B | 1.71B | 2.24B | 1.97B | 2.1B |
| Gross Profit | 13.35B | 10.47B | 10.87B | 12.23B | 12.24B |
| Gross Margin | 83.1% | 86.0% | 82.9% | 86.1% | 85.4% |
| Research & Development | 2.62B | 3.06B | 3.99B | 5.23B | 5.85B |
| Selling, General & Admin | 1.82B | 2.12B | 2.54B | 2.95B | 2.7B |
| Operating Expenses | 4.4B | 5.08B | 6.52B | 8.24B | 8.66B |
| Depreciation & Amortization | 286.2M | 341.4M | 421M | 482.9M | 543.7M |
| EBITDA | 9.67B | 5.26B | 4.69B | 5.32B | 5.82B |
| EBITDA Margin | 60.2% | 43.2% | 35.8% | 37.4% | 40.6% |
| Operating Income | 8.95B | 5.39B | 4.35B | 3.99B | 3.58B |
| Operating Margin | 55.7% | 44.2% | 33.2% | 28.1% | 24.9% |
| Interest Income | 0 | 160.1M | 495.9M | 711.4M | 716.8M |
| Interest Expense | 57.3M | 59.4M | 73M | 55.2M | 43.8M |
| Other Income / Expenses | 379M | (526.8M) | (149.3M) | 789.2M | 1.65B |
| Income Before Tax | 9.33B | 4.86B | 4.2B | 4.78B | 5.23B |
| Pre-Tax Margin | 58.0% | 39.9% | 32.0% | 33.7% | 36.5% |
| Income Tax Expense | 1.25B | 520.4M | 245.7M | 367.3M | 725.8M |
| Net Income | 8.08B | 4.34B | 3.95B | 4.41B | 4.5B |
| Net Margin | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| EPS (Basic) | 76.40 | 40.51 | 37.05 | 40.90 | 43.07 |
| EPS (Diluted) | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 |
| Weighted Avg Shares | 105.7M | 107.1M | 106.7M | 107.9M | 104.6M |
| Weighted Avg Shares (Diluted) | 112.2M | 113.5M | 113.7M | 115.1M | 108.6M |
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
Intrinsic Alpha fair value
Locked
Current Price
$945.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.